Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
INVESTOR ALERT: The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Leerink Partnrs Has Positive Outlook of REGN Q4 Earnings
Investment analysts at Leerink Partnrs increased their Q4 2024 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, January 28th. Leerink Partnrs analyst ...
Investor's Business Daily on MSN1d
Investing Action Plan: A Big Week For Biotechs, Pharma And Econ, Plus Amazon And Alphabet
The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...
Bernstein cuts Regeneron stock price target to $1,000, keeps Outperform
Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...
Regeneron's SWOT analysis: stock faces eylea challenges amid pipeline promise
Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...
Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
TD Cowen cuts Regeneron stock price target to $1,030
TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 ...
Regeneron Pharmaceuticals (REGN) Investor Alert: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Piper Sandler Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,013.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target cut by research analysts at Piper Sandler from $1,195.00 to $1,013.00 in a report issued on Monday,Benzinga reports. The ...
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...